Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H27NO3 |
Molecular Weight | 293.4012 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
InChI
InChIKey=DQKXQSGTHWVTAD-UHFFFAOYSA-N
InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3
Pramoxine (also known as pramocaine or pramoxine HCI) is a topical anesthetic and antipruritic. Pramoxine is used to temporarily relieve itching and pain caused by minor skin irritation such as minor burns/cuts/scrapes, sunburn, eczema, insect bites, cold sores, or rashes from poison ivy, poison oak, or poison sumac. Some products containing pramoxine are also used to temporarily relieve the itching and discomfort from hemorrhoids and certain other problems of the genital/anal area (such as anal fissures, itching around the vagina/rectum). Pramocaine is available by itself and in combination with other medications in various topical preparations. It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation. Pramoxine reversibly binds and inhibits voltage gated sodium channels on neurons decreasing sodium permeability into the cell. This stabilizes the membrane and prevents ionic fluctuations needed for depolarization stopping any action potential propagation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.drugbank.ca/drugs/DB09345 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PRAMOSONE Approved UseUse for the temporary relief of pain and itching associated with minor lip or skin irritations (e.g., dermatoses, insect bites, minor burns or sunburns, minor cuts or scrapes, cold sores, hives, rashes due to poison ivy, poison oak, or poison sumac) Launch Date1976 |
PubMed
Title | Date | PubMed |
---|---|---|
Screening topical antipruritics: a histamine-induced itch human model. | 2002 Jul-Aug |
|
Contact irritant dermatitis and anti-pruritic agents: the need to address the itch. | 2003 Apr |
|
Anorectal drug products for over-the-counter human use. Final rule. | 2003 Aug 26 |
|
Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. | 2003 Jun |
|
Childhood shingles. Herpes zoster can occur in healthy children too. | 2004 Apr |
|
An evaluation of the moisturizing and anti-itch effects of a lactic acid and pramoxine hydrochloride cream. | 2004 Feb |
|
Uncovering tinea incognito. Topical corticosteroids can mask typical features of ringworm. | 2004 Jul |
|
Lack of burning and stinging from a novel first-aid formulation applied to experimental wounds. | 2004 Mar-Apr |
|
Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide. | 2005 Nov |
|
OTC product: Monistat Soothing Care for vaginial discomfort. | 2005 Nov-Dec |
|
Treating itch in psoriasis. | 2006 Jun |
|
Evaluation of pramoxine ingestion as reported to poison centers. | 2006 May |
|
Acquiring tetanus after hemorrhoid banding and other gastrointestinal procedures. | 2007 Apr |
|
Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine. | 2007 Feb |
|
Perioral dermatitis. | 2008 |
|
A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. | 2009 |
|
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009 Dec 2 |
|
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. | 2009 Feb 18 |
|
Psychological interventions in the management of common skin conditions. | 2010 |
Patents
Sample Use Guides
Adults
Dermatologic Conditions
Topical
As self-medication: Apply gel, lotion, ointment, or solution to the affected area up to 3 or 4 times daily.
Fixed combination with hydrocortisone: Apply cream, lotion, or ointment to the affected area as a thin film 3 or 4 times daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/932995
Pramoxine (1.36 x 10(-5) M) caused attenuation of the response to substance P, the responses to acetylcholine, histamine and barium chloride in guinea-pig ileum.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
||
|
WHO-ATC |
C05AD07
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
||
|
WHO-ATC |
D04AB07
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
||
|
WHO-VATC |
QC05AD07
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
||
|
WHO-VATC |
QD04AB07
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
34347
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
C61903
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
Pramoxine
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
100000081415
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
SUB09994MIG
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
068X84E056
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
DTXSID8040692
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
C005548
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
3487
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
DB09345
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
8357
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
205-425-7
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
140-65-8
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
PRAMOCAINE
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
235
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
m9099
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
4886
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
068X84E056
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL1198
Created by
admin on Sat Dec 16 17:05:23 GMT 2023 , Edited by admin on Sat Dec 16 17:05:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)